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Abstract
Sustained inflammation upon chronic liver injury induces the development of liver fibrosis in mice and men.
Experimental models of liver fibrosis highlight the importance of hepatic macrophages, so-called Kupffer cells, for
perpetuating inflammation by releasing proinflammatory cytokines and chemokines as well as activating hepatic
stellate cells (HSC). Recent studies in mice demonstrate that these actions are only partially conducted by liver-
resident macrophages, classically termed Kupffer cells, but largely depend on recruitment of monocytes into the
liver. Monocytes are circulating precursors of tissue macrophages and dendritic cells (DC), which comprise two
major subsets in blood, characterized by the differential expression of chemokine receptors, adhesion molecules
and distinct markers, such as Ly6C/Gr1 in mice or CD14 and CD16 in humans. Upon organ injury, chemokine
receptor CCR2 and its ligand MCP-1 (CCL2) as well as CCR8 and CCL1 promote monocyte subset accumulation in
the liver, namely of the inflammatory Ly6C
+ (Gr1
+) monocyte subset as precursors of tissue macrophages. The
infiltration of proinflammatory monocytes into injured murine liver can be specifically blocked by novel anti-MCP-1
directed agents. In contrast, chemokine receptor CX3CR1 and its ligand fractalkine (CX3CL1) are important negative
regulators of monocyte infiltration in hepatic inflammation by controlling their survival and differentiation into
functionally diverse macrophage subsets. In patients with liver cirrhosis, ‘non-classical’ CD14
+CD16
+ monocytes are
found activated in blood as well as liver and promote pro-inflammatory along with pro-fibrogenic actions by the
release of distinct cytokines and direct interactions with HSC, indicating that the findings from murine models can
be translated into pathogenesis of human liver fibrosis. Moreover, experimental animal models indicate that
monocytes/macrophages and DCs are not only critical for fibrosis progression, but also for fibrosis regression,
because macrophages can also degrade extracellular matrix proteins and exert anti-inflammatory actions. The
recently identified cellular and molecular pathways for monocyte subset recruitment, macrophage differentiation
and interactions with other hepatic cell types in injured liver may therefore represent interesting novel targets for
future therapeutic approaches in liver fibrosis.
Introduction
Chronic liver inflammation is a major health problem
worldwide, eventually resulting in liver fibrosis, end-stage
liver cirrhosis, organ failure, hepatocellular carcinoma
and ultimately death. In industrialized countries, chronic
hepatitis C, alcohol abuse and non-alcoholic steatohepa-
titis (NASH) are major causes for liver cirrhosis [1]. Liver
fibrosis commonly develops as a result of chronic organ
inflammation which is characterized by the infiltration
and activation of immune cells, leading to both inflam-
matory as well as wound healing responses including
subsequent necrosis and apoptosis of parenchymal cells
and replacement by connective tissue and extracellular
matrix (ECM) proteins. Although the different etiologies
of liver fibrosis (e.g., alcohol abuse, chronic viral hepatitis,
metabolic syndrome and autoimmune disorders) employ
different mechanisms of hepatocyte injury, the resulting
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be astonishingly similar despite the very different disease
onsets [2].
Over recent years, several studies have emphasized the
crucial role of infiltrating monocytes for the progression
of liver inflammation and fibrosis in experimental mouse
models [3-7]. It has become clear that the macrophage
compartment of the liver, traditionally called ‘Kupffer
cells’, is constantly replenished to a significant extent by
blood monocytes [1,8] and is greatly augmented by an
overwhelming number of infiltrating monocytes upon
acute or chronic liver injury [4,9]. During fibrosis pro-
gression in mice, monocyte-derived macrophages can
release several cytokines perpetuating chronic inflamma-
tion as well as directly activate hepatic stellate cells
(HSC), resulting in their proliferation and transdifferen-
tiation into collagen-producing myofibroblasts [3,4,7].
Nevertheless, it has to be kept in mind that liver-resident
macrophages (Kupffer cells) may be capable of proliferat-
ing under certain condition s[ 1 0 ] .H o w e v e r ,u pt on o w
this Kupffer cell proliferation has only be observed in
inflammatory conditions that are extremely skewed
towards “type 2” responses (T-helper cell 2/interleukin-4
driven conditions), such as parasitic infections [10], rais-
ing the question whether local macrophage proliferation
could be of general relevance in liver fibrosis as well [11].
This review will discuss recent evidence from our labora-
tory about the functional role of monocyte subsets for
liver inflammation and fibrosis as well as distinct chemo-
kine actions driving monocyte migration and differentia-
tion that may possibly represent novel therapeutic targets
in hepatic fibrosis.
Monocyte subsets in men and mice
Monocytes represent about 5-10% of peripheral blood
leukocytes in humans and mice. They originate from a
myeloid precursor in the bone marrow, circulate in the
blood, bone marrow and spleen, and then enter tissues
[12,13]. Monocytes are regarded as circulating precursors
for tissue macrophages and dendritic cells (DCs). Migra-
tion of monocytes into tissues and differentiation into
macrophages or DCs is believed to be largely determined
by the inflammatory milieu, i.e. adhesion molecules, che-
mokines and pathogen-associated pattern-recognition
receptors [12].
Heterogeneity among human monocytes was recog-
nized over twenty years ago [14]. The differential expres-
sion of CD14 (part of the receptor for lipopolysaccharide)
and CD16 (also known as FcgRIII) were used to define
two major subsets in peripheral blood: ‘classical’ CD14
+
+CD16
- monocytes, typically representing up to 95% of
the monocytes in healthy individuals, and the ‘non-classi-
cal’ CD14
+CD16
+ cells comprising the remaining fraction
of monocytes [15]. These subsets differ in many respects,
including adhesion molecule and chemokine receptor
(CCR) expression. CD14
++CD16
- monocytes express
CCR2, CD62L (L-Selectin) and FcgRI (CD64), whereas
CD14
+CD16
+ monocytes lack CCR2, and have higher
levels of MHC-II and FCgRII (CD32). Both subsets
express the receptor for fractalkine, CX3CR1, but
CD14
+CD16
+ monocytes characteristically express higher
levels [13,16].
More recently, it was noted that different monocyte
subpopulations also exist in mice [17]. Based on similar
adhesion molecule and chemokine receptor as well as
similar gene expression profiles, murine Ly6C
hi (Gr1
hi)
monocytes are considered counterparts of human CD14
++CD16
- monocytes, and murine Ly6C
lo (Gr1
lo)m a y
represent the subpopulation comparable to human
CD16
+ monocytes [16]. More recently, human CD16
+
monocytes have been further subdivided into ‘intermedi-
ate’ CD14
+CD16
+ and ‘non-classical’ CD14
dimCD16
++
cells [18], with the latter likely sharing important func-
tional similarities to murine Ly6C
lo monocytes [19].
Migratory and functional differences of monocyte
subsets
Based on a distinct pattern of chemokine receptors
expressed on their surface, both monocyte subsets show
fundamentally different patterns in their migratory beha-
vior. Namely, the chemokine receptors CCR1 and CCR2
are more highly expressed on Ly6C
hi mouse monocytes,
whereas CCR5 and CX3CR1 are elevated on murine
Ly6C
lo monocytes [13,16,20]. Both subsets constitutively
patrol the blood vessels of the entire circulation and
also to some extent the secondary lymphatic system.
Monocytes therefore are able to act as ‘first responders’
to inflammatory signals, infiltrating inflamed tissues
shortly after the onset of injury. This process has mainly
been observed for Ly6C
hi monocytes and is highly
dependent on chemokine receptors CCR2 and CCR6
[21-23]. CCR2 has been described to mediate release of
Ly6C
hi monocytes from the bone marrow as well as
driving tissue infiltration directly [20,24-26], whereas
CCR6 (ligand: CCL20) seems to be of some importance
for guiding infiltrating cells to the site of injury once the
monocytes have left the bloodstream e.g. in inflamed
skin areas [23,27,28]. In injured liver, the chemokine
receptor CCR8 appears to be also critical for Ly6C
hi
monocyte accumulation and subsequent pro-inflamma-
tory macrophage differentiation in vivo [29]. Ly6C
hi
monocytes are rapidly recruited to sites of inflammation,
such as in atherosclerosis, peritonitis, urinary tract infec-
tion or after organ damage into the injured liver
[4,20,24,30,31]. Within the inflamed tissue, Ly6C
hi
monocytes were found to give rise to pro-inflammatory
macrophages and TNF-producing DCs in inflamed
tissue [4,12,20,26,31].
Tacke Fibrogenesis & Tissue Repair 2012, 5(Suppl 1):S27
http://www.fibrogenesis.com/content/5/S1/S27
Page 2 of 8In contrast, Ly6C
lo monocytes appear to have a more
patrolling behavior at the endothelium [32]. Imaging stu-
dies using intravital microscopy in dermis tissue suggested
that Ly6C
lo cells scarcely leave blood vessels without
inflammatory stimuli, but rather showed a patrolling beha-
viour rolling along endothelia in a LFA-1 and CX3CR1
dependent fashion [17]. Ly6C
lo monocytes have also been
found to migrate into the inflamed intima in atherosclero-
t i cp l a q u e sw h e r et h e yp r e f e r e n t i a l l yd i f f e r e n t i a t ei n t o
‘non-classical’ CD11c
+ macrophages [20]. Other studies
indicated that Ly6C
lo monocytes may serve as precursors
for alternatively activated macrophages, possibly fulfilling
functions in tissue repair and resident macrophage/DC
turnover [12,32,33]. A natural reservoir for Ly6C
lo mono-
cytes in vivo appears to be the spleen [34].
The origin of ‘non-classical’ Ly6C
lo monocytes is contro-
versially debated among monocyte researchers. It is appar-
e n tt h a tL y 6 C
lo monocytes can develop from Ly6C
hi
monocytes as a more mature subset [35,36], and the ‘con-
version’ from Ly6C
hi to Ly6C
lo monocytes likely takes
place in the bone marrow under homeostatic conditions
[36]. However, experimental data exist indicating that
Ly6C
lo monocytes may also in parallel arise from distinct
precursors in the bone marrow, independent from the
Ly6C
hi subset [12,30,37]. From experimental hepatological
research, very limited data exist about the functional role
of Ly6C
lo monocytes, but it has to be mentioned that infil-
trating, inflammatory Ly6C
hi monocytes rapidly downre-
gulate Ly6C surface expression upon transmigration into
(injured) liver [4,38].
Role of CCR2 and CCR8 for monocyte infiltration
in liver fibrosis
Accumulating evidence from murine models demon-
strated that the infiltration of monocytes into the liver is a
major pathogenic factor for chronic hepatic inflammation
and fibrosis [3-6]. In order to identify the role of monocyte
subsets in hepatic fibrosis, we characterized subpopula-
tions of infiltrating monocytes in acute and chronic carbon
tetrachloride (CCl4)-induced liver injury in mice using
flow-cytometry and immunohistochemistry [4]. Inflamma-
tory Ly6C
hi,b u tn o tL y 6 C
lo monocytes were massively
recruited into the liver upon toxic injury constituting an
up to 10-fold increase in CD11b
+F4/80
+ intrahepatic
macrophages early (24-48 hours) after CCl4 injection and
persistently a 3- to 5-fold increase in fibrotic livers at 6
weeks after biweekly CCl4 injections. During chronic liver
damage, intrahepatic CD11b
+F4/80
+Ly6C
+ monocyte-
derived cells differentiated preferentially into iNOS-produ-
cing macrophages exerting proinflammatory and profibro-
genic actions, e.g. promoting hepatic stellate cell (HSC)
activation, TH1-T cell differentiation and transforming
growth factor beta (TGFb)-release [4].
Because Ly6C
hi monocytes express high levels of CCR2
[20] and activated hepatic stellate cells were shown to
release high amounts of the CCR2-ligand MCP-1 [39,40],
we compared wildtype with CCR2- and CCR2/CCR6-defi-
cient mice in the CCl4 fibrosis model in order to identify
possible chemokine receptor pathways mediating mono-
cyte migration into the liver. These experiments revealed
that the chemokine receptor CCR2 critically controls
intrahepatic Ly6C
hi monocyte accumulation, at the level of
mediating their egress from the bone marrow. Impaired
monocyte subset recruitment in CCR2
-/- and CCR2
-/-
CCR6
-/- mice resulted in reduced HSC activation and
diminished liver fibrosis. Moreover, adoptively transferred
Ly6C
hi monocytes traffic into the injured liver and pro-
mote fibrosis progression in wildtype and CCR2
-/-CCR6
-/-
mice, which are otherwise protected from hepatic fibrosis.
Intrahepatic CD11b
+F4/80
+Ly6C
+ monocyte-derived
macrophages purified from CCl4-treated animals, but not
‘naïve’ bone marrow monocytes or control lymphocytes,
directly activate HSC in a TGFb-dependent manner in
vitro [4]. Collectively, these data indicate that inflamma-
tory Ly6C
+ monocytes, recruited into the injured liver via
CCR2-dependent bone marrow egress, promote the pro-
gression of liver fibrosis (Figure 1).
Several independent studies highlighted the importance
of the chemokine receptor CCR2 and its cognate ligand
monocyte-chemoattractant protein 1 (MCP-1/CCL2) for
monocyte recruitment during experimental hepatic fibro-
sis [3-6], suggesting that inhibition of CCR2 or MCP-1
might bear therapeutic potential in hepatic fibrosis. There-
fore, we have investigated the pharmacological inhibition
of MCP-1 via the structured L-enantiomeric RNA oligo-
nucleotide mNOX-E36 (a so-called Spiegelmer) that
potently binds and inhibits murine MCP-1 in two murine
models of chronic liver diseases [41]. Antagonizing MCP-
1 by mNOX-E36 efficiently inhibited murine monocyte
chemotaxis in vitro as well as migration of Ly6C
+ blood
monocytes into liver upon injury in vivo. In line with
lower levels of intrahepatic macrophages, pro-inflamma-
tory cytokines (TNF, IFNg,I L - 6 )w e r es i g n i f i c a n t l y
reduced in injured liver tissue, and the development of
steatosis and steatohepatitis was ameliorated by anti-
MCP-1 treatment [41].
Moreover, CCR1 and CCR5, receptors for the che-
mokines CCL3/MIP1a,C C L 4 / M I P 1 b and CCL5/
RANTES, were found to promote liver fibrosis in mice
[9]. Of note, while the function of CCR1 could be
attributed to infiltrating immune cells (most likely
Ly6C
+ monocytes), CCR5 appears to exert its actions
primarily on resident hepatic non-parenchymal cells,
most probable on HSC [9]. Recent experimental data
from our laboratory indicate that the chemokine recep-
tor CCR8 (main ligand: CCL1) is also involved in
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injured liver and in promoting preferential differentia-
tion into macrophages with a pro-inflammatory pheno-
type [29]. CCR8-deficient mice showed significantly
reduced hepatic fibrosis in two independent experi-
mental models, which was accompanied by reduced
intrahepatic monocytes/macrophages and could be
restored by adoptively transferring CCR8-expressing
Ly6C
hi bone marrow monocytes [29].
Role of CX3CR1 for macrophage differentiation in
liver fibrosis
The chemokine receptor CX3CR1 is expressed at high
levels on both monocyte subsets (Ly6C
lo>>Ly6C
hi)a n d
has been identified as an important regulator of mono-
cyte migration, differentiation and survival [13]. Preli-
minary observations have linked CX3CR1 and its ligand
fractalkine (CX3CL1) to the pathogenesis of chronic
liver diseases. As such, fractalkine and CX3CR1 were
found up-regulated in biopsies of patients with acute
and chronic liver injury [42], especially in cholestatic
diseases [43,44]. Furthermore, CX3CR1 gene polymorph-
isms have been associated with fibrosis progression in
patients with chronic hepatitis C [45]. Experimentally,
shedding of CX3CL1 by HSC promoted chemoattraction
of monocytes in vitro [46], and the adhesion of human
CD16
+ monocytes to liver sinusoidal endothelium was
partially mediated by CX3CR1 [47]. We therefore set
out experiments to define the role of fractalkine and
CX3CR1 for liver inflammation and fibrosis.
To analyze the functional relevance of this pathway, two
models of experimental liver fibrosis were applied to wild-
type (WT) and CX3CR1-deficient mice, namely repetitive
carbon tetrachloride (CCl4) injections as well as surgical
ligation of the biliary duct (BDL, bile duct ligation) [48].
Upon liver injury in mice, fractalkine expression was
induced, primarily in hepatocytes and hepatic stellate cells
(HSC). CX3CR1
-/- developed greater hepatic fibrosis than
WT animals in CCl4- and BDL-induced fibrosis. Surpris-
ingly, CX3CR1
-/- mice displayed significantly increased
numbers of monocyte-derived macrophages within the
injured liver. Bone marrow transplanted chimeric animals
revealed that CX3CR1 restricts hepatic fibrosis progression
and monocyte accumulation through mechanisms exerted
by infiltrating immune cells. In the absence of CX3CR1,
intrahepatic monocytes developed preferentially into pro-
inflammatory TNF- and iNOS-producing macrophages
(Figure 1) [48]. This impact on differentiation has been
also observed by in-vitro experiments, which demon-
strated increased TNF and reduced arginase-1 expression
Figure 1 Monocyte subsets in experimental liver fibrosis in mice. Upon liver injury, hepatocytes, hepatic stellate cells, endothelium and
resident macrophages (Kupffer cells) release many cytokines and chemokines (not shown in detail). CCL2 is an important mediator that
promotes the accumulation of inflammatory CCR2
+ Ly6C
hi (Gr1
hi) monocytes from blood into the injured liver. CCR8 and its ligand CCL1 also
promote monocyte/macrophage migration in hepatic fibrosis. Intrahepatic monocytes develop preferentially into ‘M1’ inflammatory
macrophages in this setting. These monocytes/macrophages release proinflammatory cytokines such as TNFa, IL1b or IL6 that further promote
hepatocyte apoptosis, hepatocyte steatosis and inflammation, but also directly interact with hepatic stellate cells via TGFb, thereby contributing
to myofibroblast transdifferentiation and collagen production. CX3CL1-CX3CR1 interactions on monocytes/macrophages are anti-inflammatory
and anti-fibrotic by prolonging monocyte survival and limiting M1 macrophage differentiation.
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stimulation [49].
Although CX3CL1 was originally defined as a chemoat-
tractant for monocytes [20,50] a growing body of evidence
indicated that CX3CR1 is involved in controlling cell survi-
val. In conditions of hepatic inflammation and fibrosis,
CX3CR1 represents an essential survival signal for hepatic
monocyte-derived macrophages by activating anti-apopto-
tic bcl-2 expression [48]. Monocytes/macrophages lacking
CX3CR1 undergo increased cell death following liver
injury, which then perpetuates inflammation, promotes
prolonged inflammatory monocyte infiltration into the
liver and results in enhanced liver fibrosis [48]. Taken
together, CX3CR1 limits liver fibrosis in vivo by controlling
differentiation and survival of intrahepatic monocytes
(Figure 1). Pharmacological augmentation of this pathway
may thus represent a possible therapeutic antifibrotic
strategy [51].
Role of monocyte subsets for fibrosis regression
Although infiltrating monocytes/macrophages have clearly
been shown to contribute to the progression of fibrosis in
vivo (see above), they appear to be capable of acting as
important beneficial contributors to fibrosis regression as
well [51]. The selective depletion of macrophages, using a
transgenic mouse model with diphtheria toxin receptor
expression on myeloid (CD11b
+) cells, during the resolu-
tion phase after CCl4-induced injury significantly impaired
resolution of fibrosis [7]. This effect could be mainly
attributed to reduced expression of matrix metalloprotei-
nase (MMP) 13 (collagenase 3) by scar-associated macro-
phages, which is the key enzyme to degrade excessive
extracellular matrix proteins [52]. Moreover, macrophage
derived elastase MMP-12 regulates the degradation of
elastin, which is a major ECM component characterizing
advanced fibrosis/cirrhosis [53]. It is very likely that these
beneficial actions are largely conducted by specifically dif-
ferentiated monocyte-derived cells, because the adoptive
transfer of macrophage subsets into (regressing) experi-
mental fibrosis was shown to improve hepatic fibrosis in
mice [54]. Similarly, distinct subpopulations of myeloid
(likely monocyte-derived) dendritic cells have been
observed during fibrosis regression, which also function-
ally facilitated hepatic fibrosis regression upon adoptive
transfer experiments in mice [55]. However, the exact phe-
notype of infiltrating monocytes and monocyte-derived
cells during fibrosis regression and its potential for cell-
based therapeutic approaches in humans demands further
investigations.
Translation of findings from murine models into
human pathogenesis
The recent advances in understanding the role of mono-
cyte subsets and macrophage actions in murine
experimental hepatic fibrosis raised the question whether
these mechanisms can be directly translated into human
pathogenesis. CCL2-CCR2 interactions had long been
suggested as an important mediator of macrophage accu-
mulation in human liver diseases as well [56]. As the
interference with monocyte subset infiltration, differen-
tiation and activation may represent an interesting novel
target for future therapeutic approaches in liver fibrosis
[1], our laboratory aimed at defining the functional con-
tributions of monocyte subpopulations to liver fibrogen-
esis in human liver disease as well. We therefore
analyzed circulating monocyte subsets from freshly
drawn blood samples of 226 patients with chronic liver
disease (CLD) and 184 healthy controls by FACS analysis
[57]. Circulating monocytes were significantly expanded
in CLD-patients compared to controls with a marked
increase of the ‘non-classical’ CD14
+CD16
+ subset. These
CD14
+CD16
+ monocytes showed an activated phenotype
in patients (e.g., increased HLA-DR expression) and cor-
related with proinflammatory cytokines and clinical pro-
gression. Correspondingly, CD14
+CD16
+ macrophages
massively accumulated in fibrotic/cirrhotic livers, as evi-
denced by immune-fluorescence and FACS from biopsies
and explanted cirrhotic livers. Ligands of monocyte-
related chemokine receptors CCR2, CCR1 and CCR5
were expressed at higher levels in fibrotic and cirrhotic
livers, while CCL3 and CCL4 were also systemically ele-
vated in CLD-patients [57]. Fractalkine was significantly
up-regulated in the circulation upon disease progression,
while CX3CR1 was down-regulated intrahepatically in
patients with advanced liver fibrosis or cirrhosis [48].
H o w e v e r ,i th a st ob ek e p ti nm i n dt h a td e s p i t em a n y
similarities the chemokine system between mice and men
do not fully overlap. As such, interleukin-8 (IL-8,
CXCL8), a potent chemoattractant for neutrophils and
ligand for the receptors CXCR1 and CXCR2, has no
direct homologue in mice. IL-8 is strongly upregulated in
the livers and the serum of patients with liver fibrosis
[58]. Interestingly, IL-8 does not seem to primarily pro-
mote neutrophil attraction during fibrogenesis, but rather
contributes to accumulation of monocytes in fibrotic
livers, as circulating monocytes in patients with cirrhosis
significantly upregulate CXCR1 on their surface [58].
We also isolated human monocyte/macrophage sub-
populations from healthy volunteers and patients with
liver cirrhosis to functionally characterize these subsets
regarding cytokine/chemokine expression and interac-
tions with primary human hepatic stellate cells (HSC) in
vitro. CD14
+CD16
+ monocytes released abundant proin-
flammatory cytokines. Furthermore, CD14
+CD16
+,b u t
not CD14
+CD16
- monocytes could directly activate col-
lagen-producing HSC [57].
Given the assumption that CD14
+CD16
+ monocytes
would resemble Ly6C
lo cells in mice [13], our findings
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m o u s em o d e l s ,b e c a u s ef i b r o s i si n d u c t i o na n dp r o g r e s -
sion in mice is accompanied by Ly6C
hi monocytosis in
peripheral blood and infiltration of Ly6C
hi monocytes
into the injured liver [4]. The reasons for this discrepancy
are currently unknown. One obvious difference between
murine models and the human diseased liver is the strik-
ingly dissimilar time-course of fibrosis development.
Whereas experimental murine fibrosis is analyzed at
three or six weeks after induction, e.g. by BDL or CCl4
injection, human fibrosis and cirrhosis usually develops
over decades of chronic injury and inflammation, and the
most prominent enrichment of CD14
+CD16
+ monocytes
were apparent in end-stage cirrhosis [57]. On the other
hand, the assumption that CD14
+CD16
+ human mono-
cytes are equivalents of murine Ly6C
lo m o n o c y t e si sp r i -
marily based on conserved gene and protein profiles
between these subsets [16], but not on functional assays.
In more functional approaches, only CD14-low expres-
sing CD16
+ monocytes (so called CD14
dim cells) dis-
played characteristics of murine Ly6C
lo monocytes [19].
Our experiments demonstrated that murine Ly6C
hi
monocyte-derived cells in inflammatory conditions and
human CD14
+CD16
+-derived macrophages share impor-
tant functional properties, particularly the expression of
pro-inflammatory cytokines such as TNFa or nitric
oxide, and the ability to directly activate HSC [4,57].
With respect to human hepatofibrogenesis, our data
demonstrate the expansion of CD14
+CD16
+ monocytes in
the circulation and liver of CLD-patients upon disease
progression and suggest their functional contribution to
the perpetuation of intrahepatic inflammation and profi-
brogenic HSC activation in liver cirrhosis. The modulation
of monocyte-subset recruitment into the liver via chemo-
kines/chemokine receptors and their subsequent differen-
tiation may therefore indeed represent promising
approaches for therapeutic interventions in human liver
fibrosis [51].
Conclusions
Monocytes are circulating cellular precursors for macro-
phages and dendritic cells. In mice and men, monocyte
subpopulations have been identified that differ with
respect to migratory and functional behaviour. Accumulat-
ing experimental evidence recently emphasized that the
infiltration of inflammatory monocyte subsets is a key fac-
tor for the progression of hepatic inflammation and fibro-
sis in injured murine liver. CCR2 and CX3CR1 have been
identified as critical, partially counteracting chemokine
pathways regulating monocyte migration and differentia-
tion in hepatofibrogenesis. In patients with chronic liver
diseases and cirrhosis, non-classical CD14
+CD16
+ mono-
cytes exert pro-inflammatory and pro-fibrogenic actions.
The therapeutic targeting of monocyte/macrophages by
interfering with their migration (chemokine inhibitors)
and differentiation or by direct cell transplantation during
progression and regression of fibrosis are currently under
intense investigation.
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